AMERICAN FORK, Utah, April 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage biopharmaceutical company with a novel AI-assisted drug discovery platform technology, today announced it will present five posters at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. AACR poster presentation details are below:
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date and Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM
Location: Poster Section 52
Abstract Presentation Number: LB161
Session Category: Experimental and Molecular Therapeutics
Session Title: New Compounds and Drug Targets
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM
Location: Poster Section 27
Abstract Presentation Number: 4649
Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models" Session Category: Experimental and Molecular Therapeutics
Session Title: HDAC and Methyltransferase Inhibitors
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM
Location: Poster Section 24
Abstract Presentation Number: 4587
Title: "Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma" Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session Date and Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PM
Location: Poster Section 54
Abstract Presentation Number: LB444
Presenter: Hariprasad Vankayalapati
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Biologic Therapies and Therapeutics Targets
Session Date and Time: Tuesday Apr 9, 2024 1:30 PM – 5.00 PM
Location: Poster Section 27
Abstract Presentation Number: 5957
Presenter: Yesenia Barrera-Millan & Haiyong Han
More information can be found on the AACR meeting website.
For more information, please visit www.biolexistx.com.